Goldman Sachs’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $53.7M | Sell |
952,820
-273,794
| -22% | -$17.8M | 0.01% | 1522 |
|
|
2025
Q4 | $98.3M | Buy |
1,226,614
+643,860
| +110% | +$43.3M | 0.01% | 1004 |
|
|
2025
Q3 | $28.4M | Sell |
582,754
-61,746
| -10% | -$3.82M | ﹤0.01% | 1910 |
|
|
2025
Q2 | $48.1M | Buy |
644,500
+181,019
| +39% | +$12M | 0.01% | 1364 |
|
|
2025
Q1 | $29.5M | Sell |
463,481
-231,815
| -33% | -$15.8M | ﹤0.01% | 1665 |
|
|
2024
Q4 | $54.3M | Buy |
695,296
+113,011
| +19% | +$9.08M | 0.01% | 1222 |
|
|
2024
Q3 | $46.8M | Sell |
582,285
-35,147
| -6% | -$2.84M | 0.01% | 1304 |
|
|
2024
Q2 | $51.1M | Buy |
617,432
+456,286
| +283% | +$40.1M | 0.01% | 1151 |
|
|
2024
Q1 | $13.8M | Sell |
161,146
-30,107
| -16% | -$2.36M | ﹤0.01% | 2171 |
|
|
2023
Q4 | $16.4M | Buy |
191,253
+24,394
| +15% | +$2.11M | ﹤0.01% | 2095 |
|
|
2023
Q3 | $14.9M | Sell |
166,859
-28,983
| -15% | -$2.59M | ﹤0.01% | 2035 |
|
|
2023
Q2 | $16.7M | Buy |
195,842
+17,933
| +10% | +$1.52M | ﹤0.01% | 2003 |
|
|
2023
Q1 | $14.7M | Sell |
177,909
-70,894
| -28% | -$5.74M | ﹤0.01% | 2072 |
|
|
2022
Q4 | $19.6M | Buy |
248,803
+108,252
| +77% | +$8.7M | ﹤0.01% | 1982 |
|
|
2022
Q3 | $10.4M | Buy |
140,551
+44,034
| +46% | +$3.16M | ﹤0.01% | 2465 |
|
|
2022
Q2 | $6.29M | Sell |
96,517
-30,113
| -24% | -$1.78M | ﹤0.01% | 2918 |
|
|
2022
Q1 | $8.01M | Buy |
126,630
+10,111
| +9% | +$550K | ﹤0.01% | 2911 |
|
|
2021
Q4 | $6.18M | Buy |
116,519
+13,297
| +13% | +$810K | ﹤0.01% | 3198 |
|
|
2021
Q3 | $7.29M | Buy |
103,222
+30,753
| +42% | +$1.94M | ﹤0.01% | 3020 |
|
|
2021
Q2 | $4.83M | Sell |
72,469
-44,009
| -38% | -$3.11M | ﹤0.01% | 3372 |
|
|
2021
Q1 | $12.9M | Sell |
116,478
-4,322
| -4% | -$535K | ﹤0.01% | 2328 |
|
|
2020
Q4 | $14.3M | Sell |
120,800
-23,415
| -16% | -$2.52M | ﹤0.01% | 2146 |
|
|
2020
Q3 | $12.6M | Sell |
144,215
-6,271
| -4% | -$548K | ﹤0.01% | 2118 |
|
|
2020
Q2 | $13.5M | Sell |
150,486
-662,254
| -81% | -$66.9M | ﹤0.01% | 2021 |
|
|
2020
Q1 | $81M | Buy |
812,740
+468,153
| +136% | +$50.8M | 0.03% | 598 |
|
|
2019
Q4 | $39.6M | Buy |
344,587
+26,105
| +8% | +$3.16M | 0.01% | 1325 |
|
|
2019
Q3 | $40.2M | Buy |
318,482
+25,610
| +9% | +$3.25M | 0.01% | 1262 |
|
|
2019
Q2 | $35.2M | Buy |
292,872
+77,002
| +36% | +$7.58M | 0.01% | 1403 |
|
|
2019
Q1 | $18.9M | Buy |
215,870
+35,913
| +20% | +$3.27M | 0.01% | 1920 |
|
|
2018
Q4 | $18M | Buy |
179,957
+34,097
| +23% | +$3.58M | 0.01% | 1887 |
|
|
2018
Q3 | $16.7M | Sell |
145,860
-242,714
| -62% | -$25.1M | ﹤0.01% | 2059 |
|
|
2018
Q2 | $34.8M | Buy |
388,574
+223,561
| +135% | +$18.9M | 0.01% | 1491 |
|
|
2018
Q1 | $12.1M | Buy |
165,013
+6,527
| +4% | +$448K | ﹤0.01% | 2194 |
|
|
2017
Q4 | $9.21M | Buy |
158,486
+30,240
| +24% | +$1.59M | ﹤0.01% | 2515 |
|
|
2017
Q3 | $5.75M | Buy |
128,246
+75,725
| +144% | +$3.15M | ﹤0.01% | 3013 |
|
|
2017
Q2 | $2.07M | Sell |
52,521
-85,876
| -62% | -$3.53M | ﹤0.01% | 3809 |
|
|
2017
Q1 | $5.62M | Buy |
138,397
+3,056
| +2% | +$119K | ﹤0.01% | 2836 |
|
|
2016
Q4 | $5.44M | Sell |
135,341
-87,469
| -39% | -$3.3M | ﹤0.01% | 2975 |
|
|
2016
Q3 | $8.07M | Sell |
222,810
-9,673
| -4% | -$332K | ﹤0.01% | 2630 |
|
|
2016
Q2 | $6.74M | Buy |
232,483
+1,355
| +0.6% | +$41K | ﹤0.01% | 2630 |
|
|
2016
Q1 | $8.09M | Buy |
231,128
+211,341
| +1,068% | +$6.83M | ﹤0.01% | 2382 |
|
|
2015
Q4 | $638K | Sell |
19,787
-34,715
| -64% | -$1.13M | ﹤0.01% | 4702 |
|
|
2015
Q3 | $1.76M | Buy |
54,502
+23,426
| +75% | +$882K | ﹤0.01% | 3925 |
|
|
2015
Q2 | $1.29M | Sell |
31,076
-129,345
| -81% | -$5.45M | ﹤0.01% | 4295 |
|
|
2015
Q1 | $7.21M | Buy |
160,421
+148,219
| +1,215% | +$6.2M | ﹤0.01% | 2564 |
|
|
2014
Q4 | $457K | Sell |
12,202
-12,158
| -50% | -$445K | ﹤0.01% | 5368 |
|
|
2014
Q3 | $851K | Sell |
24,360
-75,766
| -76% | -$2.7M | ﹤0.01% | 4768 |
|
|
2014
Q2 | $3.53M | Buy |
100,126
+83,947
| +519% | +$2.8M | ﹤0.01% | 3405 |
|
|
2014
Q1 | $527K | Sell |
16,179
-89,218
| -85% | -$3.41M | ﹤0.01% | 5237 |
|
|
2013
Q4 | $4.44M | Buy |
105,397
+21,984
| +26% | +$905K | ﹤0.01% | 3208 |
|
|
2013
Q3 | $3.33M | Buy |
83,413
+56,375
| +209% | +$2.37M | ﹤0.01% | 3388 |
|
|
2013
Q2 | $1.12M | Buy |
+27,038
| New | +$1.09M | ﹤0.01% | 4301 |
|
Other funds holding HAE
VPM
VCM
RRAM
Goldman Sachs's HAE Position: Q1 2026 in Review
Goldman Sachs reduced its Haemonetics (HAE) stake by 22% in Q1 2026, selling an estimated $17.8M and leaving 952,820 shares worth $53.7M. The position accounts for 0.01% of the portfolio, ranked #1522.
Goldman Sachs first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $98.3M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Goldman Sachs held 952,820 shares of Haemonetics worth $53.7M as of Q1 2026.
- Goldman Sachs sold 273,794 Haemonetics shares in Q1 2026, an estimated $17.8M.
- Haemonetics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1522 holding.
- Goldman Sachs first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Haemonetics position peaked at $98.3M in Q4 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.